The United Laboratories International Holdings Limited

HKEX
3933
Stock
Yield per half year: +22.02%
Dividend yield: 8.04%
Sector: Healthcare

Company Analysis The United Laboratories International Holdings Limited

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Dividends (8.04%) are higher than the sector average (4.32%).
  • The stock's return over the last year (83.88%) is higher than the sector average (0%).
  • Current debt level 12.15% is below 100% and has decreased over 5 years from 31.82%.
  • The company's current efficiency (ROE=19.61%) is higher than the sector average (ROE=3.98%)

Disadvantages

  • Price (15.74 HK$) is higher than fair price (14.39 HK$)

Similar companies

Hansoh Pharmaceutical Group Company Limited

Grand Pharmaceutical Group Limited

WuXi AppTec Co., Ltd.

3SBio Inc.

2. Share price and performance

2.1. Share price

2.3. Market efficiency

The United Laboratories International Holdings Limited Healthcare Index
7 days 4.8% -1.1% 2%
90 days 13.2% 0.2% 14.5%
1 year 83.9% 0% 37.8%

3933 vs Sector: The United Laboratories International Holdings Limited has outperformed the "Healthcare" sector by 83.88% over the past year.

3933 vs Market: The United Laboratories International Holdings Limited has outperformed the market by 46.08% over the past year.

Stable price: 3933 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.

Long period: 3933 with weekly volatility of 1.61% over the past year.

3. Summary of the report

3.1. General

P/E: 7.9
P/S: 1.53

3.2. Revenue

EPS 1.46
ROE 19.61%
ROA 11.35%
ROIC 0%
Ebitda margin 19.19%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (15.74 HK$) is higher than the fair price (14.39 HK$).

Price is higher than fair: The current price (15.74 HK$) is 8.6% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (7.9) is lower than that of the sector as a whole (37.2).

P/E vs Market: The company's P/E (7.9) is lower than that of the market as a whole (43.79).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (1.46) is lower than that of the sector as a whole (1.93).

P/BV vs Market: The company's P/BV (1.46) is lower than that of the market as a whole (1.59).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (1.53) is lower than that of the sector as a whole (4.03).

P/S vs Market: The company's P/S indicator (1.53) is lower than that of the market as a whole (2.5).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (3.19) is higher than that of the sector as a whole (2.91).

EV/Ebitda vs Market: The company's EV/Ebitda (3.19) is lower than that of the market as a whole (9.93).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 55.67% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (55.67%).

Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).

5.4. ROE

ROE vs Sector: The company's ROE (19.61%) is higher than that of the sector as a whole (3.98%).

ROE vs Market: The company's ROE (19.61%) is higher than that of the market as a whole (2.89%).

5.5. ROA

ROA vs Sector: The company's ROA (11.35%) is higher than that of the sector as a whole (2.89%).

ROA vs Market: The company's ROA (11.35%) is higher than that of the market as a whole (3.12%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).

ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (20.88%).

6. Finance

6.1. Assets and debt

Debt level: (12.15%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 31.82% to 12.15%.

Excess of debt: The debt is not covered by net income, percentage 117.99%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

High yield: The dividend yield of the company 8.04% is higher than the average for the sector '4.32%.

7.2. Stability and increase in payments

Dividend stability: The company's dividend yield 8.04% has been steadily paid over the past 7 years, DSI=0.93.

Dividend growth: Company's dividend yield 8.04% has been growing over the last 5 years. Growth over 6 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (38.26%) are at a comfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum The United Laboratories International Holdings Limited

9.3. Comments